📊 MAIA Key Takeaways
Is MAIA a Good Investment? Thesis Analysis
MAIA is a pre-revenue biotech company with severe financial distress, burning cash rapidly with negative operating cash flow of -$18.8M while holding minimal cash reserves. The company exhibits unsustainable economics with no revenue generation, massive operating losses (-$24.3M), and deteriorating equity position that threatens viability without immediate capital raise.
Why Buy MAIA? Key Strengths
- Minimal long-term debt exposure reduces leverage risk
- Modest current ratio of 1.66x suggests some near-term liquidity buffer
- Recent insider activity indicates ongoing company engagement
MAIA Investment Risks to Consider
- Zero revenue with $24.3M operating losses creates unsustainable burn rate
- Cash balance reported at $0.00 creates imminent liquidity crisis
- Severely negative ROE (-942.7%) and ROA (-230.8%) indicate capital destruction
- Free cash flow of -$18.8M with no revenue growth pathway in sight
- Stockholders equity of only $2.4M provides minimal buffer for ongoing losses
- Pre-clinical stage biotech with no clear path to revenue within planning horizon
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestones
- Upcoming capital raise requirements and terms
- Operating expense management and cash preservation efforts
MAIA Financial Metrics
💡 AI Analyst Insight
MAIA Biotechnology, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MAIA Profitability Ratios
MAIA vs Healthcare Sector
How MAIA Biotechnology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MAIA Overvalued or Undervalued?
Based on fundamental analysis, MAIA Biotechnology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MAIA Balance Sheet & Liquidity
MAIA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MAIA Biotechnology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.05 indicates the company is currently unprofitable.
MAIA Growth Metrics (YoY)
MAIA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$1.5M | $-0.49 |
| Q2 2022 | N/A | -$1.0M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MAIA Capital Allocation
MAIA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MAIA Biotechnology, Inc. (CIK: 0001878313)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MAIA
What is the AI rating for MAIA?
MAIA Biotechnology, Inc. (MAIA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAIA's key strengths?
Claude: Minimal long-term debt exposure reduces leverage risk. Modest current ratio of 1.66x suggests some near-term liquidity buffer.
What are the risks of investing in MAIA?
Claude: Zero revenue with $24.3M operating losses creates unsustainable burn rate. Cash balance reported at $0.00 creates imminent liquidity crisis.
What is MAIA's revenue and growth?
MAIA Biotechnology, Inc. reported revenue of $0.0.
Does MAIA pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
Where can I find MAIA SEC filings?
Official SEC filings for MAIA Biotechnology, Inc. (CIK: 0001878313) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAIA's EPS?
MAIA Biotechnology, Inc. has a diluted EPS of $-0.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MAIA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MAIA Biotechnology, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MAIA stock overvalued or undervalued?
Valuation metrics for MAIA: ROE of -942.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MAIA stock in 2026?
Our dual AI analysis gives MAIA Biotechnology, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAIA's free cash flow?
MAIA Biotechnology, Inc.'s operating cash flow is $-18.8M, with capital expenditures of N/A.
How does MAIA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -942.7% (avg: 15%), current ratio 1.66 (avg: 2).